Cancer Archives

tedopi nsclc lung cancer ose pharma atlante

News and Trends 8 Feb 2016

French Biotech Launches Phase III Global Trial for Lung Cancer Drug

OSE Pharma (France) has initiated the US phase III trial, Atalante 1. This global, pivotal trial will evaluate Tedopi, the company’s lead product, for advanced non-small cell lung cancer (NSCLC). The phase III study was initiated in Europe in early 2016, so the screening of eligible patients diagnosed with non-small cell lung cancer is now actively ongoing in […]

February 8, 2016 - 2 minutesmins - By Dani Bancroft

riboxx life sciences rna cancer tollys biotech

News and Trends 5 Feb 2016

German RNA Specialist Could Break French Biotech into the Cancer Ecosystem

Riboxx Life Sciences (Germany) has licensed out its drug development platform APOXXIM to a small biotech, Tollys SAS in Lyon (France) to investigate a specific type of cancer therapy. Riboxx develops customized and tailor-made molecular tools for gene silencing in vitro and in vivo through RNA interference via small interfering RNA (siRNA) and microRNA (miRNA). The company has two […]

February 5, 2016 - 2 minutesmins - By Dani Bancroft

pierre fabre fund innovation biotech pharma

News and Trends 3 Feb 2016

France’s 3rd Largest Pharma Company Finally Opens up to Biotech Innovation

Open Innovation is now everywhere, even Pharma. So, just today in France, the opening of the Pierre Fabre Fund for Innovation for biotech startups has been announced. Most Big Pharma have their own program. Boehringer-Ingelheim for example is partnering with BioMedX to run a new program with researchers from Heidelberg. Now the 3rd largest Pharma company in France, […]

February 3, 2016 - 2 minutesmins - By Philip Hemme

msd cancer research uk monash crt merck australia

News and Trends 1 Feb 2016

New Discovery unites Australia, Germany and UK Against Blood Cancers

Cancer Research UK has teamed up with MSD (Merck) and the Wellcome Trust to co-develop some Inhibitors for both Cancerous and Non-cancerous blood disorders from the Australian Academia-Biotech Network. The Australian Co-operative Research Centre (CRC) for Cancer Therapeutics (CTx) in Melbourne has a range of investigational inhibitors for blood disorders – including Leukemia. CTx is collaborative partnership […]

February 1, 2016 - 2 minutesmins - By Dani Bancroft

oxford biotech biomedica novartis car t cancer

News and Trends 1 Feb 2016

World CAR-T Leader Starts New Program with a UK Biotech

Pretty impressive CAR-T news coming from across the Channel… Oxford BioMedica just launched a second collaboration with Novartis, which has shown tremendous Phase II results – and the most advanced in CAR-T therapy in development so far (read our review on how CAR-T works and who else is working the field). This collaboration covers the […]

February 1, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 29 Jan 2016

Biotech of the week: Vivia Biotech, the Spanish Pioneer in Personalised Medicine

This week we leave the cold winds of Sweden and head south, to warmer weather and say ¡Hola! to Spain and the location for this week, Madrid. This vibrant city is famous for one of the best football teams in the world, the oldest restaurant in the world (opened in 1725!) and is home to the […]

January 29, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 28 Jan 2016

Viral Immunotherapy Trial Failure Causes French Biotech Stocks to Drop 43%

Genticel (France) is a clinical biotech developing a cervical cancer immunotherapy against the Human papillomavirus. However, their 24-month phase II trial has failed to meet primary endpoint at its halfway point, and their stocks dropped 43% overnight. Around 70% of cervical cancer cases are caused by 2 types of Human papillomavirus (HPV): 16 and 18. And among the 300 million women around the […]

January 28, 2016 - 3 minutesmins - By Dani Bancroft

merck msd keytruda immunoncology lymphoma hodgkins affimed

News and Trends 26 Jan 2016

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Affimed in Heidelberg (Germany) will fund and conduct a clinical trial to investigate the combination of Merck’s (MSD) anti-PD-1 therapy (Keytruda), with Affimed’s proprietary drug for the treatment of patients with Hodgkin lymphoma. The phase Ib trial will focus on patients whose disease has relapsed or is refractory to chemotherapy, including treatment with the marketed antibody-drug-conjugate […]

January 26, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Jan 2016

2011-2015: What a Fantastic 5 Years for European Biotech

The crisis of 2008 hit the Biotech sector hard, and it wasn’t clear how the Biotech industry would get back on track. But now, end of 2015, we can definitely say the Biotech industry did extremely well and probably better than most of the analysts would have predicted… So what were the major news stories […]

January 26, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 25 Jan 2016

This Potential First in Class Cancer Therapy Could Help Patients Avoid Eye Surgery

Immunocore in Oxford (UK) has been Granted Orphan Drug Designation for a Phase I Super rare Eye cancer drug by the FDA. Uveal melanoma is a rare disease in which cancer cells form in the tissues of the eye, and comprises approximately 3% of all melanomas. It is actually the primary intraocular malignancy of the adult eye and currently, […]

January 25, 2016 - 2 minutesmins - By Dani Bancroft

open evolution machine biohacking turbidostat johann bauerfeind digital

News and Trends 25 Jan 2016

Nature’s Machines: Biohacking Evolution to Destroy Pollutants

The Concept of artificially ‘Driving Evolution’ is as contagiously controversial as it is captivating for Biotechs, DIY Biologists and iGEM teams alike. How can we harness an ‘Evolution Machine’ for the Greener Good and ‘create’ microbes to break down pollutants? At the Digital Biology (“Do it Together”) Conference last week (a European consortium for DIY Biologists and […]

January 25, 2016 - 5 minutesmins - By Dani Bancroft

md anderson mologen cancer lung colorectal

News and Trends 21 Jan 2016

Mologen Joins the Rapidly Growing List of EU Partners with the No#1 US Cancer Hospital

MD Anderson (US) and the Berlin Biotech Mologen (Germany) have now partnered on for an Immuno-Oncology program fighting colorectal and small-cell lung carcinoma. The University of Texas MD Anderson Cancer Center is ‘One of the world’s most respected centres‘ devoted exclusively to cancer patient care, research, education and prevention. Having partnered with various European research institutions, medical centres […]

January 21, 2016 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

French Biotech Launches Phase III Global Trial for Lung Cancer Drug

German RNA Specialist Could Break French Biotech into the Cancer Ecosystem

France’s 3rd Largest Pharma Company Finally Opens up to Biotech Innovation

New Discovery unites Australia, Germany and UK Against Blood Cancers

World CAR-T Leader Starts New Program with a UK Biotech

Biotech of the week: Vivia Biotech, the Spanish Pioneer in Personalised Medicine

Viral Immunotherapy Trial Failure Causes French Biotech Stocks to Drop 43%

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

2011-2015: What a Fantastic 5 Years for European Biotech

This Potential First in Class Cancer Therapy Could Help Patients Avoid Eye Surgery

Nature’s Machines: Biohacking Evolution to Destroy Pollutants

Mologen Joins the Rapidly Growing List of EU Partners with the No#1 US Cancer Hospital

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!